Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy
A multi-center, single-arm. Phase 2 exploratory trial to evaluate the efficacy and safety of HM61713 as the 1st-line anticancer agent in none-small cell lung cancer patients with EGFR mutation
Non Small Cell Lung Cancer
DRUG: HM61713
Objective response rate, To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1, At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year
Progression-free survival, To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1, At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year|Disease control rate, To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1, At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year|overall survival, To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1, At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year|Time to progression, To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1, At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year|Maximum decrease in tumor size, To obtain a assessment of anti-tumor activity of HM61713 by evaluation of tumor response using RECIST version 1.1, At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 1 year|Quality of life questionnaire, At baseline and every visit, expected average 1 year
HM-EMSI-201 study targets NSCLC patients with EGFR mutations by HM61713 anticancer drug as the first-line therapy.